Cipher Pharmaceuticals Inc
PHE
Company Profile
Business description
Cipher Pharmaceuticals Inc is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company is building its business through product acquisitions, out-licensing and in-licensing arrangements. Its products include Dermatology Products, Hospital Acute Care Products, specialty medicines, and Out-Licensed Products among others. The company's geographical operational areas include Canada and the United States.
Contact
5750 Explorer Drive
Suite 404
MississaugaONL4W 0A9
CANT: +1 905 602-5840
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
6
Stocks News & Analysis
stocks
AI lands a blow on some Aussie stocks – yet stands to benefit others
AI is reshaping ASX tech moats - but some are more insulated than others.
stocks
This might be the best core stock bargain in the US market today
Patient investors should consider building a position in this wide-moat stock while it’s seriously undervalued.
stocks
Data center demand drives strong earnings outlook for SGM
Sims guides huge earnings upgrade as data center metals demand spikes.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,552.20 | 76.60 | 0.90% |
| CAC 40 | 7,665.62 | 142.25 | -1.82% |
| DAX 40 | 22,380.19 | 459.37 | -2.01% |
| Dow JONES (US) | 45,577.47 | 443.96 | -0.96% |
| FTSE 100 | 9,918.33 | 145.17 | -1.44% |
| HKSE | 24,444.50 | 832.82 | -3.29% |
| NASDAQ | 21,647.61 | 443.08 | -2.01% |
| Nikkei 225 | 51,582.23 | 1,790.30 | -3.35% |
| NZX 50 Index | 12,896.50 | 93.49 | -0.72% |
| S&P 500 | 6,506.48 | 100.01 | -1.51% |
| S&P/ASX 200 | 8,365.40 | 81.90 | 0.99% |
| SSE Composite Index | 3,871.11 | 85.95 | -2.17% |